<p>Our latest podcast explores the innovative approach of neoadjuvant immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential benefits for melanoma patients are being realised.</p>
<p>Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates.</p>
<p>In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss:</p>
<ul>
<li>the benefits of checkpoint inhibitor immunotherapy</li>
<li>the role of the pathologist in the assessment of neoadjuvant tissue</li>
<li>the impact of surgical decision-making as neoadjuvant becomes mainstay treatment</li>
<li>options for treatment-refractory patients</li>
<li>the role of checkpoint inhibitor immunotherapy in non-melanoma skin cancer.</li>
</ul>
<p>The discussion concludes with case studies to summarise key learnings.</p>
<p>This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other healthcare professionals.</p>
<p>SPEAKERS:</p>
<ul>
<li><strong>Prof Georgina Long AO - </strong>Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney</li>
<li><strong>Prof Richard Scolyer AO - </strong>Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney</li>
<li><strong>A/Prof Alexander Menzies - </strong>Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney</li>
<li><strong>A/Prof Alexander van Akkooi</strong> - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney</li>
</ul>
<p>KEY CLINICAL TRIALS</p>
<ol>
<li><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2211437">SWOG</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/35661157/">PRADO</a></li>
<li><a href="https://www.nature.com/articles/s41591-020-01211-7">OpACIN-neo</a></li>
<li><a href="https://clinicaltrials.gov/ct2/show/NCT04949113">NADINA</a></li>
</ol>
<p>FURTHER EDUCATION</p>
<ul>
<li><a href="https://melanomaeducation.org.au/courses/melanoma177/">The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists </a></li>
</ul>
<p>Please note that this podcast was accurate at the time of recording (February 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.</p>
<p>MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.</p>
